State-level regulations and opioid-related health outcomes.

[1]  Dongseok Choi,et al.  Reduction in Oregon's Medication Dosing Visits After the SARS-CoV-2 Relaxation of Restrictions on Take-home Medication , 2021, Journal of addiction medicine.

[2]  N. Dasgupta,et al.  Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19 , 2020, Journal of Substance Abuse Treatment.

[3]  E. Wang,et al.  Methadone for Opioid Use Disorder-Decades of Effectiveness but Still Miles Away in the US. , 2020, JAMA psychiatry.

[4]  M. Fingerhood,et al.  Lessons from COVID 19: Are we finally ready to make opioid treatment accessible? , 2020, Journal of Substance Abuse Treatment.

[5]  C. Davis,et al.  Opioid Policy Changes During the COVID-19 Pandemic - and Beyond , 2020, Journal of addiction medicine.

[6]  N. Menachemi,et al.  Characterizing variability in state-level regulations governing opioid treatment programs. , 2020, Journal of substance abuse treatment.

[7]  C. Davis,et al.  Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. , 2019, The International journal on drug policy.

[8]  B. Mund,et al.  Improving Rural Access to Opioid Treatment Programs , 2018, Journal of Law, Medicine & Ethics.

[9]  Rose A Rudd,et al.  Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015. , 2016, MMWR. Morbidity and mortality weekly report.

[10]  Rachel Balick.  DEA limits opioid controlled substances to be manufactured in 2017 , 2016 .

[11]  Harold Alan Pincus,et al.  Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians. , 2016, Health affairs.

[12]  J. Zibbell,et al.  Increases in Drug and Opioid Overdose Deaths—United States, 2000–2014 , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  M. Wickersham,et al.  The “Regulatory Fog” of Opioid Treatment , 2016 .

[14]  Christopher M. Jones,et al.  Vital Signs: Demographic and Substance Use Trends Among Heroin Users — United States, 2002–2013 , 2015, MMWR. Morbidity and mortality weekly report.

[15]  S. Weiner,et al.  Mandatory use of prescription drug monitoring programs. , 2015, JAMA.

[16]  H. Connery.  Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions , 2015, Harvard review of psychiatry.

[17]  K. Hempstead,et al.  Supply-side response to declining heroin purity: fentanyl overdose episode in New Jersey. , 2014, Health economics.

[18]  S. Sigmon.  Access to treatment for opioid dependence in rural America: challenges and future directions. , 2014, JAMA psychiatry.

[19]  P. Friedmann,et al.  HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations. , 2014, Health services research.

[20]  C. Thomas,et al.  Medication-assisted treatment with methadone: assessing the evidence. , 2014, Psychiatric services.

[21]  H. Hansen,et al.  Two Tiers of Biomedicalization: Methadone, Buprenorphine, and the Racial Politics of Addiction Treatment , 2012 .

[22]  Jeanmarie Perrone,et al.  Can prescription drug monitoring programs help limit opioid abuse? , 2011, JAMA.

[23]  Alexander C Wagenaar,et al.  Making the Case for Laws That Improve Health: a Framework for Public Health Law Research , 2022 .

[24]  H. W. Clark,et al.  United States Government Oversight and Regulation of Medication Assisted Treatment for the Treatment of Opioid Dependence , 2009 .

[25]  J. Chriqui,et al.  State policies matter: the case of outpatient drug treatment program practices. , 2008, Journal of substance abuse treatment.

[26]  Lori J. Ducharme,et al.  State policy influence on the early diffusion of buprenorphine in community treatment programs , 2008, Substance abuse treatment, prevention, and policy.

[27]  B. Harrison.  Prescription drug monitoring programs. , 2006, NCSL legisbrief.

[28]  Andrew N Garman,et al.  Barriers to Entrepreneurship in Healthcare Organizations , 2006, Journal of health and human services administration.

[29]  J. Jaffe,et al.  From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. , 2003, Drug and alcohol dependence.